Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
1.220
-0.040 (-3.17%)
Nov 21, 2024, 11:14 AM EST - Market open
Century Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for IPSC stock have an average target of 13, with a low estimate of 5.00 and a high estimate of 24. The average target predicts an increase of 965.57% from the current stock price of 1.22.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IPSC stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 2 | 2 | 2 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $17 → $11 | Strong Buy | Maintains | $17 → $11 | +801.64% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $5 | Strong Buy | Maintains | $9 → $5 | +309.84% | Nov 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $9 | Strong Buy | Maintains | $11 → $9 | +637.70% | Aug 15, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $12 | Buy | Maintains | $9 → $12 | +883.61% | Jun 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +801.64% | Jun 4, 2024 |
Financial Forecast
Revenue This Year
7.70M
from 2.24M
Increased by 244.52%
Revenue Next Year
9.84M
from 7.70M
Increased by 27.73%
EPS This Year
-1.72
from -2.30
EPS Next Year
-1.82
from -1.72
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 32.5M | 46.5M | 4.2M | ||
| Avg | 7.7M | 9.8M | 4.1M | ||
| Low | 2.0M | 392,000 | 3.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1,355.2% | 503.4% | -57.3% | ||
| Avg | 244.5% | 27.7% | -58.5% | ||
| Low | -12.3% | -94.9% | -60.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.67 | -1.49 | -2.01 |
| Avg | -1.72 | -1.82 | -1.95 |
| Low | -1.81 | -1.94 | -1.87 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.